Health Trials

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

ConditionsAdvanced/Metastatic Solid TumorsBladder CancerUrothelial CarcinomaAdvanced Non-Small Cell Lung CancerCarcinoma, Non Small Cell LungCarcinoma, Squamous Cell of Head and NeckHead and Neck CancerEsophageal CancerGastroesophageal Junction AdenocarcinomaEsophageal Squamous Cell CarcinomaEsophageal AdenocarcinomaPancreatic AdenocarcinomaPancreatic Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorPfizer

About this trial

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them.

The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Eligibility criteria

Qualifiers

18 years of age or older

Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas

Measurable disease

ECOG Performance status 0-1

Disqualifiers

Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )

Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion

Pulmonary disease meeting protocol exclusion

Other unacceptable abnormalities as defined by protocol

Trial design

Treatments tested in this trial

  • PF-08046876

Treatment groups

310 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Pfizer

Lead sponsor

Source ClinicalTrials.gov